



3651
1FW

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)


Total Number of Pages in This Submission

Application Number	10/522,325
Filing Date	01/25/2005
First Named Inventor	Stanley George BONNEY
Art Unit	3651
Examiner Name	Rashmi Sharma
Attorney Docket Number	PG4886-C USW

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> <input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> <input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
<p>Applicants believe that no fee is required for this submission. However, the Commissioner is hereby authorized to charge any fees required or credit any overpayment to Deposit Account No. 07-1392.</p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	GlaxoSmithKline		
Signature			
Printed name	J. Michael Strickland		
Date	March 7, 2006	Reg. No.	47,115

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Signature			
Typed or printed name	Johnie Jones	Date	March 7, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of: **Stanley George BONNEY, et al.**

Serial No.: **10/522,325**

Art Unit: **3651**

Filing Date: **01/25/2005**

Examiner: **Rashmi Sharma**

For: **Medicament Dispenser**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

Copies of the following references are enclosed. **References #25-53**
 Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
 A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

A. The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:

- (1) a final action under § 1.113 or
- (2) a notice of allowance under § 1.311,

whichever occurs first.

Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):


[] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]

[] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

[] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.
[] A duplicate copy of this paper is attached.


Respectfully Submitted,



J. Michael Strickland
Attorney of Record
Registration No. 47,115

Date: March 7, 2006
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-9024
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTORNEY DOCKET NO.		SERIAL NO.		
		PG4886-C USW		10/522,325		
		APPLICANT		Stanley George BONNEY, et al.		
		FILING DATE		GROUP		
01/25/2005		3651				



PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	3,269,389	08/30/1966	Meurer et al.			
	2.	4,627,432	12/09/1986	Newell et al.			
	3.	4,778,054	10/18/1988	Newell et al.			
	4.	4,811,731	03/14/1989	Newell et al.			
	5.	4,940,966	07/10/1990	Pettigrew et al.			
	6.	5,002,048	03/26/1991	Makiej, Jr.			
	7.	5,007,419	04/16/1991	Weinstein et al.			
	8.	5,437,267	08/01/1995	Weinstein et al.			
	9.	5,462,205	10/31/1995	Keller			
	10.	5,497,765	03/12/1996	Praud et al.			
	11.	5,505,704	04/09/1996	Pawelka et al.			
	12.	5,590,645	01/07/1997	Davies et al.			
	13.	5,664,557	09/09/1997	Makiej, Jr.			
	14.	5,772,085	06/30/1998	Bryant et al.			
	15.	5,778,873	07/14/1998	Braithwaite			

Continue on page 2**FOREIGN PATENT DOCUMENTS**

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	25.	1461280	02/27/1969	DE			X
	26.	1387954	03/19/1975	GB			
	27.	0372777	06/13/1990	EP			
	28.	2242134	09/25/1991	GB			
	29.	0469814	02/05/1992	EP			
	30.	92/12402	07/23/1992	PCT			
	31.	0521434	01/07/1993	EP			
	32.	4305277	08/25/1994	DE			X
	33.	96/31790	10/10/1996	PCT			
	34.	98/30332	07/16/1998	PCT			
	35.	98/34664	08/13/1998	PCT			
	36.	98/51257	11/19/1998	PCT			
	37.	2327408	01/27/1999	GB			
	38.	99/39991	08/12/1999	PCT			
	39.	00/00411	01/06/2000	PCT			
	40.	00/45879	08/10/2000	PCT			
	41.	00/64520	11/02/2000	PCT			
	42.	01/17595	03/15/2001	PCT			

Continue on page 2**OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)**

Continue on page 2

EXAMINER	DATE CONSIDERED
-----------------	------------------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

